The initial focus of HTG Therapeutics will be to identify development candidates targeting RNA or RNA modifying proteins, which could be relevant in areas such as oncology, immunology, diabetes, and rare disease. HTG’s EdgeSeq and Epi-EdgeSeq technology is a foundational element in our drug discovery programs. It enables a more highly resolved view of the transcriptome, especially aberrations in physiological states leading to disease. Utilizing recent advancements in data science, we seek to create better therapeutic candidates by assimilating RNA profiling directly into the drug discovery process.
HTG Therapeutics will leverage its transcriptomic and epi-transcriptomic profiling technology to improve the existing drug discovery process. This process currently produces a profile with close to 42,000 data points per sample in three independent data sets which includes the ability to detect changes in RNA modifications, such as N6-methyladenosine (m6A), which has been increasingly implicated in various disease states.
By leveraging HTG's unique profiling technologies earlier in the drug discovery process, HTG Therapeutics is expected to generate lead compounds faster, and with superior efficacy and toxicity profiles.
HTG Therapeutics will identify development candidates targeting RNA and RNA-modifying proteins, targets relevant in a wide range of diseases of unmet therapeutic need. The profiling of these diseases using the HTG EdgeSeq technology is an essential element in guiding these efforts. From hit to lead clinical candidate- HTG seeks to bring to the forefront the power of transcriptome profiling and data science to generate insights factoring into the selection of improved therapeutic candidates entering clinical trials.
Page last updated August 05, 2021